January 14, 2020 – Drug manufacturer Eli Lilly has announced that it will offer lower price versions of its
brand name insulin products Humalog® Mix75/25TM KwikPen® (insulin lispro protamine/insulin
January 14, 2020 – The U.S. FDA has issued a safety communication regarding Arena Pharmaceuticals’
Belviq® (lorcaserin) and Belviq® XR (lorcaserin extended release). According to the agency, these drugs may increase patients’ risk of cancer.
January 13, 2020 – The U.S. FDA has approved Numbrino® (cocaine hydrochloride nasal solution 4%), a nasal spray manufactured by Lanett Company and indicated to provide local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.
January 13, 2020 – The U.S. FDA has approved Valtoco® (diazepam nasal spray), manufactured by Neurelis Pharmaceuticals, to provide acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters, acute repetitive seizures) that are distinct from a patient's usual
January 10, 2020 – Taro Pharmaceuticals has announced the voluntary recall of one lot of Lamotrigine
100mg Tablets. Tablets in lot number 331771 (expiration date June 2021) have been found to be cross contaminated with another drug
January 9, 2020 – The U.S. FDA has approved AyvakitTM (avapritinib), manufactured by Blueprint Medicines Corporation, to treat adult patients who have unresectable or metastatic gastrointestinal
January 8, 2020 – The U.S. FDA has approved a new indication for Keytruda® (pembrolizumab), manufactured by Merck, to treat patients who are ineligible for or have elected not to undergo cystectomy and have been diagnosed with high-risk, non-muscle invasive bladder cancer (NMIBC)
January 8, 2020 – Several products used to treat gastrointestinal (GI) conditions have been voluntarily
recalled due to the presence or potential presence of N-nitrosodimethylamine (NDMA). NDMA is a known
environmental contaminant found in food and water and is considered a probable human